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ABSTRACT
The output of inhalational agents from modern vaporisers are both electronically and pneumatically
controlled. They are designed to deliver set agent concentrations accurately with low fresh gas
flows and possess enhanced safety features. The purpose of this review article is to give an
overview of three modern vaporisers, namely, the Aladin cassette vaporiser, injection vaporisers
and AnaConDa™. The Aladin cassette is integrated with Datex Ohmeda S/5 ADU and GE Aisys
anaesthesia machines. The electronic vapour control unit is incorporated within the anaesthesia
machine. The agent specific cassettes act as a detachable vaporising chamber. The system can
work as a variable bypass and measured flow vaporiser but requires a power supply to function.
Injection vaporisers can achieve the set end‑tidal agent concentration very rapidly with even
metabolic flow rates. Hence, anaesthetic depth can be rapidly altered with minimal wastage and
theatre pollution. The two types of injection vaporisers, namely, Maquet and DIVA™ are customised
to function with Maquet FLOW‑i and the Drager Zeus anaesthesia machine, respectively.
AnaConDa™ is a combination of vaporiser and humidity and moisture exchange filter which can
be fitted in the ventilatory circuit. It is primarily designed for use in intensive care for sedation and
out of operating room use.
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INTRODUCTION

integration, operation and safety features incorporated
in modern vaporisers to yield to end‑user demands.

Vaporisers are a salient component of modern
anaesthesia workstation and are integrated with the
anaesthesia workstation to match the accuracy and
safety standards. Since the evolution of the anaesthesia
machine into a workstation, the vaporisers have
evolved too; integrating electronics with pneumatics.
These electronic vaporisers have been made very
safe for use and have incorporated different priority
alarms to warn the end‑user whenever there is a
malfunction. In addition, with the use of more potent
volatile agents and agents with low boiling points,
the modern vaporisers have the ability to control the
vapour output with extreme accuracy even when the
anaesthesia machine fresh gas flows (FGF) are changed
to alter the anaesthetic depth rapidly. The high‑end
anaesthesia workstations have an option to set the
target end‑tidal anaesthetic concentration (ETAC)
and these vaporisers are designed to respond to such
demands with precision. Hence, this review aims to
describe the components, electronics and pneumatic

A thorough literature search was done from
inception till March 2019 using databases/search
engines (Medline, Embase, Scopus, PubMed and
Google Scholar). The articles were manually searched
by the authors for cross‑referencing. All the articles
published in English were searched. We used
the following keywords ‘anaesthesia machine’,
‘anaesthesia workstation’, ‘gas delivery’, ‘vaporisers’,
‘Aladin cassette’, ‘injection vaporiser’ and ‘AnaConDa’.
Amongst 2400 articles (review articles, primary
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manuscripts, case reports, letter to the editors and
chapters from books) the relevant information
pertinent to the topic were sorted out. The information
available is very limited and only 14 references could
be included.

cassettes are available with a colour‑coded, Easy‑Fil or
Quik‑Fil mechanism. On the other hand, desflurane
cassettes have a filling mechanism that is compatible
with Saf‑T‑Fil desflurane bottles [Figure 1a]. These
cassettes can hold up to 250 mL of liquid anaesthetic.

ALADIN CASSETTE VAPORISER

The larger rear section of the cassette is the vaporising
chamber containing the liquid anaesthetic at its
SVC (saturated vapour concentration). The cassette is a
specially designed liquid sump that requires main power
supply or battery backup and adequate oxygen and air
pressure to work. It is filled with a synthetic material
soaked in liquid anaesthetic that is arranged as lamellae
with metal plates interspersed between the lamellae.
They are so arranged to form a convoluted pathway for
the FGF so that the surface area available for vaporisation
is maximised. The back panel has an inflow valve and
outflow valve which are spring‑loaded mechanical ball
valves to prevent agent leak during transport [Figure 1b].

Aladin cassette vaporiser electronically controls
the gas flow and vapour concentration. This system
is used in the Datex Ohmeda S/5 ADU and GE
Aisys anaesthesia workstation.[1] The vaporiser
system consists of an electronic vapour control unit
internalised within the anaesthesia workstation and
coded agent cassettes that contain the anaesthetic
liquid that serves as a detachable vaporising chamber.
The cassettes are coloured and magnetically coded
and are designed to deliver five different inhalational
anaesthetics (halothane, isoflurane, enflurane,
sevoflurane and desflurane).
The structural and functional components: The
Aladin cassette comprises of two parts, namely,
the agent‑specific vaporiser chamber (cassette) and
the central processing unit (CPU) which is integrated
into the anaesthesia machine. The cassette is a
leakproof metal box which has a smaller front portion
which is colour‑coded to the specific agent and a larger
rear portion that is black in colour. The front portion
has an agent‑specific filling system, a glass window
to display the level of the anaesthetic liquid and a
handle with a lever for locking the cassette in the slot
provided on the anaesthesia machine. This portion
also houses the contact for the electronic temperature
sensor and liquid anaesthetic agent level. There are
four copper coloured circles that can be seen on the
top surface of the front of the cassettes. These are the
copper contacts of the electronic bus that power the
capacitor plates which sense the level of the liquid
agent. Information from the liquid level sensor and
vaporiser temperature data is transmitted by this
electronic bus to the anaesthesia workstation. There
are also five agent identification magnets arranged in a
sequence in the front portion of the cassette, but these
are not visible externally. These signature magnets
allow the anaesthesia machine to identify the agent
cassette that is inserted into the machine slot.
There are three types of Aladin 2 cassettes (which are
currently used in modern anaesthesia workstations)
filler systems. Enflurane and isoflurane use a
colour‑coded, Easy‑Fil mechanism. Sevoflurane

Functional Anatomy: The Aladin cassette vaporiser is
concentration calibrated, flow over and electronically
thermo‑compensated that works both as variable
bypass and measured flow vaporiser.[2,3]
Function as a variable bypass: Aladin cassette vaporiser
is in many ways similar to the other variable bypass
vaporisers such as Tec 4, Tec 5 and Tec 7 vaporisers,
however, there are several important differences. The
vaporiser consists of (a) a bypass chamber which
houses a backpressure regulator that builds pressure
at the input to the vaporiser if necessary, to drive gas
through the cassette, and this is permanently housed
in the anaesthesia machine and (b) a detachable
cassette that serves as the vaporising chamber. The
two separate parts must come together to form a
functioning vaporiser. The liquid anaesthetic is
filled in the front section and enters the rear section
through a one‑way valve. The FGF and the vaporiser
output are electronically controlled with the necessary
hardware and software built into the anaesthesia
machine [Figure 2].

a

b

Figure 1: Desflurane Aladin Cassette Vaporiser. (a) Front panel
showing the Saf‑T‑filling mechanism compatible with Desflurane
bottles (b) Rear panel with inflow and outflow spring‑loaded mechanical
valves
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Figure 2: Schematic illustration explaining the components and basic functional aspect of Aladin 2 cassette vaporiser. FGF = Fresh gas flow

Gas flow: The FGF is first split into two portions; the
bulk of the FGF passes through the bypass chamber
and a smaller portion passes through a mechanical
one‑way valve and an electronic inflow close valve.
It then enters the cassette by passing through the
open mechanical ball valve in the rear panel of the
cassette. This cassette inflow valve only opens when
the cassette is plugged into the slot in the anaesthesia
machine. The FGF enters the vaporising chamber to
pick up vapour at its saturated vapour pressure (SVP).
The gas saturated with anaesthetic vapour exits the
cassette/vaporising chamber through the cassette
outflow valve and passes sequentially through an
electronic outflow close valve, a liquid flow prevention
valve and a proportional flow valve. Finally, it passes
through the agent flow measurement device and into
the outlet of the control unit, gets mixed with the
bypass chamber gas and is delivered at the common
gas outlet [Figure 2].
Function as a measured flow vaporiser: To deliver
the requested concentration of the volatile agent, the
outflow from the cassette (the variable control of flow
through the cassette) is controlled by a proportional
valve. Hence, the control loop of the system
depends upon the cassette flow and not the agent
concentration (that amount of cassette flow is added
to the bypass chamber flow to meet the desired set
concentration of the volatile agent) which is delivered
to the common gas outlet [Figure 3a].
Delivery of the set agent concentration: Volatile
anaesthetic agent is delivered from the cassette‑based
on the mixer output pressure and the cassette pressure.
When the cassette pressure exceeds the mixer output
pressure the entire FGF is directed through the bypass
chamber and inflow valve closes to prevent any gas

flow to the cassette [Figure 3b]. The excess pressure
in the cassette is then brought down by metering
out some of the gas containing inhalational agent
from the cassette pressure relief valve attached to the
scavenging system. Once the cassette pressure falls
below the mixer output pressure some of the FGF is
again routed through the cassette [Figure 3c]. Hence,
the control loop will differ depending upon whether
the entire FGF is routed through the bypass chamber
or to split between cassette and bypass chamber.
When the entire FGF is through the bypass chamber,
the control loop depends on mixer flow. On the other
hand, when FGF is split between the cassette and the
bypass chamber, the control loop for delivery of the
volatile agent depends on the reported mixer flow,
cassette flow, cassette pressure and temperature.
The flowmeters: The inflow and outflow flowmeters
determine the flow by detecting the pressure
drop across a fixed flow restrictor (pressure drop
is proportional to gas flow over fixed resistance).
A zeroing valve is incorporated into each of the
flowmeters that temporarily will short the pressure
transducer’s ports together for an accurate zero
measurement. These zeroing valves also prevent agent
condensation as they are energised during standby to
heat the flowmeter manifold.
Temperature control and compensation: Vapour
concentration of the volatile agent is determined by
SVP divided by the total cassette pressure (SVP/Total
cassette pressure).[2] Hence, if the temperature falls
the SVP of the volatile agent will fall and therefore
the proportional valve will accordingly govern the gas
flow output from the cassette. Finally, temperature
compensation is achieved by the central processing
unit. The microprocessor receives input from multiple
173
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a

b

c
Figure 3: Interplay of the cassette of cassette pressure and mixer output pressure in Aladin cassette function. (a) Cassette pressure and mixer
output pressure regulating agent delivery from cassette, (b) Cassette pressure exceeds mixer output pressure and the gas flow to the cassette
is stopped (c) Cassette pressure is lowered down as agent is metered out to the scavenging system and cassette pressure falls below mixer
output pressure and the gas is routed through the cassette. FGF = Fresh gas flow, F = Flowmeter, P = Pressure sensor, Cassette pr. relief
valve = Cassette pressure relief valve

sources every 200 ms including FGF rate, carrier gas
composition, set vapour concentration, liquid level
and temperature in the vaporising chamber (sump)
and controls vapour output electronically. To maintain
cassette temperature, there is a fan mounted beneath
the Aladin cassette housing operating at cassette
temperatures below 17°C. This serves to heat the
cassette when large amounts of volatile anaesthetic are
being vaporised and heat is lost.
The difference in the delivery of desflurane vapour
compared to other agents: The desflurane Aladin cassette
works differently compared to that of other agents. When
the temperature of desflurane inside the cassette is less
than 22.8 , it functions as a flow over variable bypass
vaporiser just as it is for the other agents. However,
when the cassette temperature is above 22.8°C, which is
the boiling point of desflurane, the inflow valve closes
and no fresh gas enters the cassette. The vaporiser now
behaves as an injector and calculated amount of vapour
is injected out of the proportional valve to mix with the
fresh gas from the bypass.
Aladin 1 and Aladin 2 cassettes: There are some
differences between the originally introduced Aladin
1 cassettes [Figure 4] and the currently used Aladin 2
cassettes [Figure 2]. The liquid level display window

is bigger in Aladin 2 and the handle has a locking
lever. There is also an additional liquid level sensor
which gives input back to the anaesthesia workstation
via an electronic bus, which also conveys vaporiser
temperature data. Aladin DES and all Aladin 2
cassettes have electronic agent level sensing. Aladin
1 and Aladin 2 both measure temperature. While
Aladin 1 had very simple temperature measurement
Aladin 2 cassettes are more advanced having internal
temperature sensing mechanism. A symbol indicating
enhanced temperature sensing is seen on the front of
the cassette [Figure 2].
Salient features of Aladin Cassette
The vapour output is not influenced by atmospheric
pressure changes since the vapour concentration is
determined by the separate environment that is the
total cassette pressure. The electronic control in the
cassette allows for automatic record keeping and
usage calculation. Agent control is monitored by the
microprocessor up to 200 ms during operation. Aladin
cassette vaporiser is electronically controlled hence, it
cannot function in the presence of power failure when
the workstation battery gets depleted.
Aladin cassette is featured with specific safety features
to ensure safe and constant delivery of vapours to the
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pollution. Injection vaporisers were introduced with
high‑end anaesthesia workstations (Maquet FLOW‑i and
Drager Zeus).

Figure 4: Schematic illustration explaining the components and basic
functional aspect of Aladin 1 cassette vaporiser. FGF = Fresh gas flow,
Cassette ID = Cassette identification

patients. The cassette features with accurate overfill
protection and the level sensing are electronic and
more accurate than only visual sensing. There is
a liquid spill prevention valve that prevents the
anaesthetic liquid in the vaporising chamber from
entering the fresh gas line. There is no risk of agent
spilling if the cassette is tilted as the inlet valve will
close preventing any spillage. The vaporiser undergoes
a daily self‑check automatically when the anaesthesia
workstation is switched on. Aladin cassette also has
a pressure relief valve that works as a safety valve
that opens whenever the pressure inside the Aladin
cassette is greater than 2.5 bar.
Foong et al.[4] reported an accidental over‑delivery of
desflurane via Aisys Carestation Aladin 2 Cassette™
vaporiser. The inspired fraction of desflurane (FiDes)
went up to 17.5% and 19.5% on two occasions during
a procedure in end‑tidal control delivery mode. Both
episodes were managed by temporarily switching
off desflurane and washing off desflurane with high
FGF (6 l/min). The patient developed hypotension and
tachycardia and required pharmacological intervention
for restoration of haemodynamic parameters. Changing
the cassette did not resolve the issues. However, similar
situations could not be simulated later except on one
occasion and it was classified as an intermittent error.
Hence, vigilance is necessary while using automated
drug delivery devices.

INJECTION VAPORISERS
Injection vaporisers[5,6] inject a known amount of liquid
agent or pure vapour into the gas stream to provide desired
concentration. The hallmark of injection vaporiser is that
it enables rapid titration of anaesthetic depth with highly
conservative low gas flows (metabolic flow) in a very
short time (as short as 1 min), as a result, they minimise
the wastage of the anaesthetic agents and prevent theatre

It is worthwhile to know how the injection vaporiser
can achieve the set targets of rapidly altering
anaesthetic depth in 1 min with exceptionally low FGF.
Rapid anaesthetic depth titration with low FGF can be
achieved by first calculating the amount of sevoflurane
vapour required to achieve 2% ETAC of sevoflurane
in approximately 6000 mL capacity reservoir which is
120 mL of vapour (120/6000 × 100 = 2%) where the
reservoir comprises of patient’s functional residual
capacity of 2000 mL and the anaesthesia circle breathing
system capacity of 4000 mL. With a sevoflurane
vaporiser set at 2%, the splitting ratio is 12:1. With FGF
of 6000 mL/min, 5538 mL/min flows through the bypass
chamber and 462 mL/min flows through the vaporising
chamber and picks up 120 mL/min of sevoflurane
vapour. The total vaporiser output is 6120 mL/min and
sevoflurane will represent ~2% of that output.[7]
Hence, the percentage of sevoflurane vapour that
a vaporiser should deliver to achieve 2% ETAC
of sevoflurane in 1 min with 180 mL of FGF is
equal to sevoflurane vapour/total FGF that is,
120/(180 + 120) = 0.4 or 40% where 180 mL is the near
metabolic FGF (3.5 mL/kg in a 50 kg person ~180 mL)
and 120 mL is the sevoflurane vapour added to FGF.
Thus, a vaporiser will have to deliver 40% sevoflurane
in FGF of 180 mL to achieve the 2% ETAC of sevoflurane
in 1 min. None of the vaporisers except the injection
vaporisers can achieve this target in such a short time
with near metabolic FGF.
Working principle: The anaesthetic agent is dispensed
as liquid and that liquid has to be converted into the
vapour state. Thus, the working principle involves
the calculation of how much vapour will be generated
by 1 mL of an anaesthetic agent. For example, the
molecular weight of isoflurane is 184.5 and its specific
gravity is 1.5 g/mL. Hence, applying Avogadro’s
hypothesis 184.5 g/moles of isoflurane will occupy
22.4 L at 273 K or 0and 760 mmHg. Therefore, 1 g/mole
at 20 will occupy 22400/184.5 × 293/273 and 1 mL
will give 22400/184.5 × 293/273 × 1.5 = 194 mL of
isoflurane vapour.[8]

MAQUET INJECTION VAPORISER
The structural and functional components [Figure 5]:
This is an electronically controlled injection type of
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Figure 5: Schematic representation of components and function of
Maquet injection vaporiser. VC temp. sensor = Vaporising chamber
temperature sensor, Heating foil temp. sensor = Heating foil
temperature sensor, S = sensor, R = Receiver

vaporiser that is used exclusively with the Maquet
FLOW‑i anaesthesia machine. The vaporisers weigh
3.2 kg and are available for isoflurane, sevoflurane and
desflurane.
The vaporiser consists of a liquid fill reservoir (container)
with an agent capacity of 300 mL but at 260 mL it gives
an indication of being 100% full. The electronic level
indicator shows the anaesthetic liquid level with the
help of a float in the illuminated metered tube. There
are LEDs mounted at 6 different levels corresponding
to 5, 10, 25, 50, 75 and 100%. The low and medium
priority alarm is triggered at the level of 10 and 5%,
respectively. However, the vaporiser does not switch
off when it is empty. The vaporiser does not have a
concentration control dial. The liquid container can
be filled with an anaesthetic agent via filling port that
has a safety fill valve to handle the pressure inside the
liquid container. The safety valve is designed to handle
different manufacturer’s specifications and filling
systems (Isoflurane: Key fill, Sevoflurane: Key fill and
Quick Fil™, Desflurane: Saf‑T‑Fil™). The vaporiser lid
covers the safety valve and the filling port. Vaporiser
lid position is monitored by a lid sensor and it must be
closed to activate the vaporiser. The liquid container
is also connected to a drive gas inlet to allow entry of
a driving gas and pressurise the liquid in the reservoir.
The liquid container is connected to the vaporising
chamber via a vaporiser injector. The liquid container
is provided by a gas escape pipe which helps to
evacuate gas bubbles from the pressurised liquid
anaesthetic before it reaches the vaporiser injector. The
vaporiser pressure transducer measures the pressure
of the liquid anaesthetic and a safety valve cuts off

the supply of the pressurised liquid to the vaporiser
injector device when the vaporiser or the system is
off or on standby. The vaporiser injector delivers the
pressurised liquid anaesthetic in the form of spray into
the vaporising chamber. A nozzle plate is placed in
front of the injector to convert the liquid into a spray.
The injector’s opening is pulse controlled to achieve
the set concentration of the anaesthetic. This pulsed
liquid anaesthetic spray is monitored by the optical
vaporiser injection device (OVID). The vaporising
chamber is heated by the vaporising heating foil for
uniform heating and converts the vapour spray into
gas. The vaporising chamber has an inlet and an outlet
for FGF. The FGF enters the vaporising chamber and
gets mixed with the vaporised anaesthetic agent. The
mixed FGF exits the vaporiser and is routed through
the patient cassette.
Functional Anatomy: Drive gas from the anaesthesia
workstation enters the liquid anaesthetic container
from the top at 120 kPa and forces the pressurised liquid
anaesthetic through a safety valve into the vaporiser
injector. The vaporiser injector injects the liquid
anaesthetic in a pulsed, intermittent manner into the
heated vaporising chamber depending upon the set and
the measured concentration. The spray is delivered in
short pulses of 0.8 mL of agent per ms and the pulse
time varies from 2–10 ms for isoflurane/sevoflurane
and 5–10 ms for desflurane. Hence, the volume of agent
injected per pulse is 1.6–8 mL for isoflurane/sevoflurane
and 4–8 µL for desflurane. The OVID contains 2 PC
boards i) vaporiser spray LED and ii) vaporiser spray
detector which detects the presence of the spray
of the anaesthetic agent into electronically heated
vaporising chamber. The temperature of the vaporising
chamber is monitored and maintained at 47°C for
isoflurane/sevoflurane and 37°C for desflurane.
Temperature of the vaporising chamber and heating
foil is measured by separate temperature sensors. 1)
The vaporising chamber temperature is monitored
by 2 vaporising temperature sensors. The vaporiser
gets switched off if the temperature of the vaporising
chamber rises above 60°C or when the temperature
difference of more than 5°C is detected between the
2 sensors, 2) When the temperature of the heating foil
goes beyond 140°C the heating foil is switched off, no
alarms are activated and the heating is restarted once
the temperature falls. But if the temperature exceeds
170°C the vaporiser is switched off and a technical
alarm is activated. The liquid rapidly evaporates in
the vaporising chamber and this vapour is carried by
the FGF coming in through the inlet valves. The mixed
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FGF exits the vaporising chamber through the outlet
valves.[5]

DRAGER DIVA (DIRECT INJECTION OF VAPOUR
ANAESTHETIC) VAPORISER
The Drager DIVA vaporiser which is integrated into the
Zeus anaesthesia machine allows for target‑controlled
anaesthesia with closed‑loop quantitative control of
the delivery of oxygen, carrier gas and anaesthetic
vapour.
Structural and functional components: The Drager DIVA
injection vaporiser can be categorised as measured
flow vaporiser. The carrier gas and the anaesthetic
agent is uncoupled and both are delivered separately
into the system [Figure 6a]. The vaporiser integrated
with the anaesthesia machine consists of 2 modules,
a detachable vaporising or metering module that
is anaesthetic specific and a fixed non‑specific gas
supply module that is inbuilt in the Zeus anaesthesia
machine. The metering module [Figure 6b] stores
the liquid anaesthetic in a reservoir with a coded
filling system, liquid level indicator window and a
ventilation outlet. It also houses a dosing chamber
that is connected to the reservoir through a liquid gate.

a

The dosing chamber, whose pressure is monitored, is
connected to the heated vaporising chamber through
a dosing valve. This dosing valve is controlled by an
electronic computer‑controlled feedback control unit,
which receives information about the FGF rate and
set anaesthetic agent concentration (either fresh gas
or ETAC). The feedback control unit thus controls the
amount of liquid injected through the dosing valve
into the heated vaporising chamber. The gas supply
module [Figure 6c] is part of the anaesthesia machine.
It consists of propellant gas (air) inlet, a non‑return
valve, a pressure buffer and pressure reducer and
a supply valve through which gas (air) enters the
metering module [Figure 6].[6]
Functional anatomy: When the vaporising module is
placed in its slot it gets integrated with the gas supply
module. The propellant gas (air) enters the metering
module and propels the liquid anaesthetic through
the liquid gate into the dosing chamber. The pressure
in the dosing chamber is transmitted to the feedback
control unit. Depending on the set agent concentration
(that is transmitted electronically from the feedback
control unit to the dosing valve) a fixed amount of
liquid anaesthetic is injected into the heated vaporising
chamber. The liquid anaesthetic is vaporised in the

b

c
Figure 6: Gas flow schematic illustration of Zeus/Zeus IE rebreathing system. (a) Illustration showing uncoupled carrier gas and direct injection
volatile agent (DIVA), both delivered separately into the circle system. (b) Schematic illustration showing the components and function of the
metering module of DIVA vaporiser. (c) Schematic illustration of the gas module within the anaesthesia machine that gets integrated with the
metering module of DIVA vaporiser during use. FGF = Fresh gas flow, APL = Adjustable pressure limiting, P = Pressure sensor
177
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heating chamber and passes through a flow sensor out
of the metering module [Figure 6b].
The anaesthetic vapours can take one of the two
pathways once they exit the metering module,
depending on the mode set on the Zeus anaesthesia
machine. If it is set at fresh gas control mode, the
vapours pass through a fresh gas valve to a mixing
chamber, where they mix with the FGF and the
mixture is directed to the breathing system. If it is
set in auto control mode, the vapours exit through
another pathway, pass through the saturated vapour
valve directly to the breathing system, where they mix
with the FGF. Thus, in auto control mode, anaesthetic
vapours and FGF are injected separately into the
breathing system while in the fresh gas control
mode; the system emulates a classical system with
flowmeter and vaporiser. The electronic feedback
control unit thus determines the amount of liquid
that would be dosed through the dosing valve into
the heated vaporisation chamber and controls the
vapour output. Hence, quantitative closed‑system
anaesthesia or target‑controlled anaesthesia can be
achieved. The blower unit (TurboVent2) is the crucial
component that creates the gas flow (inspiration) to
the patient.
Salient features of injection vaporisers
Injection
vaporisers
are
electronically
and
pneumatically operated with safety features that
switch off the vaporiser with an audiovisual technical
alarm when there is a malfunction of temperature and
pressure. The vaporiser is not vulnerable to tipping as
it has no wicks to saturate and agent cannot spill into
the vaporising chamber. Filling of the vaporiser can be
performed while the vaporiser is in use (though agent
delivery does not happen during filling).
Struys et al.[9] compared time to reach desired ETAC,
initial overshoot and stability at target ETAC and
washout time using agents desflurane and sevoflurane
between Zeus (Dräger, Lübeck, Germany) apparatus
using direct injection of inhaled anaesthetics and
Primus apparatus (Dräger, Lübeck, Germany) using a
classic out‑of‑circle vaporiser. The authors observed
that electronic control allows instantaneous changes
in vapour concentrations to achieve set ETAC values
even with very low FGF. In Zeus, the wash‑out times
were faster, inhaled anaesthetic concentration was
the lowest, no overshoot at the target was seen and
the time course of sevoflurane and desflurane was
minimally influenced by changes in FGF.

AnaConDa VAPORISER
AnaConDa™ or Anaesthetic conserving device
was the brainchild of Giebeck AB and introduced
in the market by Sedana Medical, Stockholm,
Sweden.[10] It is a miniature anaesthetic vaporiser and
HME (humidified moisture exchanger) filter combined
together. The device is meant to be used mainly for
sedation in the intensive care unit (ICU) and outside
operating rooms. It is designed to deliver only
isoflurane and sevoflurane [Figure 7].
The structural and functional components: The
AnaConDa™ the device has a colour‑coded patient
side (transparent) and a ventilator side (black)
separated by a bilayer filter. It is a unique oval‑shaped
device where the ventilator inlet and the patient outlet
are aligned parallel to the filter medium to facilitate
laminar airflow. The device is customised to fit
between the Y‑piece and endotracheal tube (ETT) like
an HME filter. The patient end has an outlet which
can be connected directly to the ETT or a connector.
The patient’s end has a gas sampling port connected
with a standard Leur lock through which end‑tidal
gas monitoring can be performed. AnaConDa™
does not require any additional power supply for its
operation [Figure 7]. The vaporiser should be placed at
an angle of 45°. Internally in the vaporiser, the first layer
of the bilayer filter is an electrostatic polypropylene
filter, a protective layer situated towards the patient
side, which prevents the ventilator from bacterial and
viral contamination. The second layer is a thick 3–4 mm
activated carbon felt adsorptive layer which adsorbs
and reflects inhalational anaesthetics and moistures
in the circuit. However, for proper functioning, the
device should be replaced daily [Figure 8a].
AnaConDa™ is available presently in two different
internal volumes of 100 and 50 mL to be used in

Figure 7: Set up of AnaConDa™ vaporiser for use
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unique thread different in diameter and look from
other commonly used medical threads so that they are
exclusively keyed to each other. Specially designed
polyoxymethylene bottle adaptors are available for
filling the syringe attached to the AnaConDa™. During
inspiration [Figure 8b], the gas in the inspiratory limb
picks up vapour from the evaporator rod and delivers
it to the patient. During expiration [Figure 8c], the
unabsorbed part of the anaesthetic vapour is absorbed
by the thick carbon filter. A major portion (as high
as 90%) of this absorbed vaporiser is delivered to
the patient again (or ‘reflected’ back) in the next
inspiration. The small amount of vapour which
reaches the expiratory limb gets scavenged eventually.
The rate of infusion of anaesthetic vapour depends on
the type of vapour used (isoflurane and sevoflurane),
patients’ mass and tidal volume used. Pharmacokinetic
models for manually adjusted infusion rates have been
tried with some success [Figure 8].[12]

a

b

c
Figure 8: Schematic cross‑section of AnaConDa™ vaporiser
(a) Schematic cross‑section illustrating the inner components of
AnaConDa™ vaporiser when switched off. (b) The flow of gases
during inspiration through the AnaConDa™ vaporiser. (c) The flow of
gases during the expiration phase through the AnaConDa™ vaporiser.
HME = Humidity moisture exchanger

patients with high and low tidal volumes, respectively.
AnaConDa™ (50 ml) is for the patients with less than
50 kg body weight and a tidal volume of fewer than
350 mL as a dead space of 100 mL will lead to inadequate
carbon dioxide washout and thus may give rise to
deleterious hypercapnia. The 50 mL device can be used
even in patients with a tidal volume as low as 200 mL.
While the 100 mL AnaConDa™ is recommended for
tidal volumes ranging from 350–1200 mL. The 50 ml
device is slightly less efficient (by approximately 2%)
than the 100 mL device, therefore, requiring a slightly
higher infusion rate for a desired end‑tidal vapour
concentration.
Functional anatomy: AnaConDa™ delivers constant
inhalational agents to the patients despite having
no measurement dials.[11] A porous polypropylene
evaporator rod is mounted to the patient’s end of the
device [Figure 8a]. The rod has an external agent line
made of polyethylene connected to a 50 mL specially
modified syringe mounted on a syringe pump. The
agent line has an adaptor with a small spring valve
which only opens when the syringe is fully fitted to
the adaptor. This safety feature prevents anaesthetic
agents from leaking backwards into the device at
the time of syringe disconnection of the syringe for
refilling. The device adaptor and the Syringe share

The AnaConDa™ devices are validated by the
manufacturers in bench‑top tests as per ISO‑9360
standards for HME and HME filters.[13] The
AnaConDa™ has a keyed system in the form of a
unique thread that connects the adaptor and the
syringe. Neither AnaConda™ can be connected to
any other syringe than the customised one nor the
syringe can be attached to any other Luer lock or other
intravenous devices. AnaConDa™ by its recycling
mechanism (activated carbon) saves anaesthetic
vapours as well as prevents environmental pollution.
Nishiyama et al. demonstrated that AnaConDa™
could save anaesthetic vapour consumption and
fasten emergence from general anaesthesia versus
conventional TEC vaporisers.[11] However, the device
has certain limitations. AnaConDa™ creates a dead
space effect larger than its internal volume due to
reflection of carbon dioxide hence, it is used in patients
with acute respiratory distress syndrome and other
respiratory illness is questionable as it limits giving
low tidal volume ventilation as well as increases the
physiological dead space.[14]
Summary: The modern vaporisers have both electronic
and pneumatic control and can deliver set or target
anaesthetic agent concentration accurately. The FGF
rates through the vaporisers may vary as in Aladin or
constant as in Flow‑I and DIVA to achieve the target
agent concentration with minimal wastage and theatre
pollution. They are designed to alleviate hazards
and ensure safe, constant and effective delivery of
inhalational anaesthetics to the patients.
179

Indian Journal of Anaesthesia | Volume 64 | Issue 3 | March 2020
Page no. 19

[Downloaded free from http://www.ijaweb.org on Tuesday, April 14, 2020, IP: 24.217.110.35]

Kundra, et al.: Modern vaporisers

Financial support and sponsorship
Nil.

8.

Conflicts of interest
There are no conflicts of interest.

9.

REFERENCES
1.
2.

3.
4.
5.

6.
7.

Hendrickx JF, De Cooman S, Deloof T, Vandeput D, Coddens J,
De Wolf AM. The ADU vaporizing unit: A new vaporizer.
Anesth Analg 2001;93:391‑5.
Boumphrey S, Marshall N. Understanding vaporizers. Contin
Educ Anaesth Crit Care Pain 2011;11:199‑203. Available from:
https://doi.org/10.1093/bjaceaccp/mkr040. [Last accessed on
2019 Feb 02].
Chakravarti S, Basu S. Modern anaesthesia vaporizers. Indian
J Anaesth 2013;57:464‑71.
Foong TW, Tan YKG. Over‑delivery of desflurane via
Aisys Carestation Aladin2 cassette vaporizer. Br J Anaesth
2018;120:1434‑5.
Riutort KT, Eisenkraft JB. The anaesthesia workstation and
delivery systems for inhaled anaesthetics. In: Barash PG,
Cullen BF, Stoelting RK, Cahalan MK, Stock MC, Ortega R
editors. Clinical Anaesthesia. 7th ed. Philadelphia: Wolters
Kluwer Health; 2013. p. 641‑96.
Davey AJ. Vaporizers. In: Davey AJ, Diba A editors. Ward’s
Anaesthetic Equipment. 6th ed. London: Saunders Elsevier;
2012. p. 41‑64.
Venticinque SG, Andrews JJ. Inhaled anaesthetics: Delivery
systems. In: Miller RD, editor. Miller’s Anaesthesia. 8th ed.

10.

11.

12.

13.

14.

Philadelphia: Elsevier Saunders; 2013. p. 752‑820.
Eisenkraft JB. Anaesthesia vaporizers. In: Ehrenwerth J,
Eisenkraft JB, Berry JM, editors. Anaesthesia Equipment:
Principles and Applications. 2nd ed. Philadelphia: Elsevier
Saunders; 2013. p. 64‑94.
Struys MM, Kalmar AF, De Baerdemaeker LE, Mortier EP,
Rolly G, Manigel J, et al. Time course of inhaled anaesthetic
drug delivery using a new multifunctional closed‑circuit
anaesthesia ventilator. In vitro comparison with a classical
anaesthesia machine. Br J Anaesth 2005;94:306‑17.
Farrell R, Oomen G, Carey P. A technical review of the history,
development and performance of the anaesthetic conserving
device “AnaConDa” for delivering volatile anaesthetic in
intensive and post‑operative critical care. J Clin Monit Comput
2018;32:595‑604.
Soro M, Badenes R, Garcia‑Perez ML, Gallego‑Ligorit L,
Marti FJ, Aguilar G, et al. The accuracy of the anaesthetic
conserving device (AnaConDa) as an alternative to the classical
vaporizer in anaesthesia. Anesth Analg 2010;111:1176‑9.
Belda JF, Soro M, Badenes R, Meiser A, Garcia ML, Aguilar G,
et al. The predictive performance of a pharmacokinetic model
for manually adjusted infusion of liquid sevoflurane for
use with the Anaesthetic‑Conserving Device (AnaConDa):
A clinical study. Anesth Analg 2008;106:1207‑14.
Nishiyama T, Kohno Y, Koishi K. Usefulness of an anaesthetic
conserving device (AnaConDa™) in sevoflurane anaesthesia.
Minerva Anestesiol 2012;78:310‑4.
Sturreson LW, Bodelsson M, Johansson A, Jonson B,
Malmkvist G. Apparent dead space with the anaesthetic
conserving device, AnaConDa: A clinical and laboratory
investigation. Anesth Analg 2013;113:1319‑24.

Announcement

Old Issues of IJA
Limited copies of old issues of IJA from 2013 are available in IJA office. Members interested can contact Editor In Chief
(editorija@yahoo.in/ijadivatia@gmail.com / 98690 77435)
180

Indian Journal of Anaesthesia | Volume 64 | Issue 3 | March 2020
Page no. 20

